Q2 Compliance Watch: Navigating FDA Supply Chain Enforcement, OTC Drug Shifts, and PBM Transparency Demands

2026-06-21

This week's TrueEval Industry Digest offers a critical look at the latest healthcare compliance mandates, from heightened FDA scrutiny on pharmaceutical supply chains to pivotal shifts in OTC drug accessibility and evolving demands for PBM transparency. Staying ahead of these changes is not merely good practice—it's essential for safeguarding your operations and patient trust in an increasingly complex regulatory landscape.

The healthcare regulatory environment is in a perpetual state of flux, demanding unwavering vigilance from telehealth innovators, national practice groups, and specialized clinics alike. This past week has underscored several critical areas where compliance, patient safety, and operational integrity intersect, signaling a period of intensified scrutiny and strategic adaptation. From the granular details of pharmaceutical labeling to the broad strokes of drug benefit management, understanding these shifts is paramount for mitigating risk and capitalizing on new opportunities.

> For more on this topic, see our analysis: [The Enforcement Nexus: DOJ's Expanding Reach, FDA's Dual Focus on Access & Safety, and CMS's PBM Probe](/blog/enforcement-nexus-doj-fda-cms-pbm-probe).

Fortifying Your Supply Chain: FDA's Unrelenting Focus on Integrity and Patient Safety

The integrity of the pharmaceutical supply chain remains a cornerstone of patient safety and regulatory compliance. The Food and Drug Administration (FDA) recently issued a final debarment order against Andrew Jonathan Morgan, prohibiting him for five years from importing or offering for import any drug into the United States. This severe action stems from a felony conviction related to drug importation, highlighting the agency's zero-tolerance stance on illicit activities that jeopardize the safety and legitimacy of pharmaceutical products.

> For more on this topic, see our analysis: [Navigating the New Enforcement Landscape: A Mid-Year Compliance Briefing for Healthcare Executives](/blog/healthcare-compliance-digest-enforcement-trends-q2-2024).

Implications for Your Practice: This enforcement action serves as a stark reminder for all healthcare entities, regardless of specialty or operational model, of the critical importance of robust due diligence in sourcing medical products. Whether you are a telehealth platform relying on partner pharmacies, a medspa purchasing injectables, or a dental or chiropractic practice acquiring therapeutic agents, the onus is on you to verify the legitimacy and regulatory standing of every link in your supply chain. Failure to do so can expose your practice to significant legal and financial liabilities, including civil monetary penalties, reputational damage, and even criminal charges if illicit sourcing is tied to patient harm.

Telehealth Brands: Scrutinize your relationships with compounding pharmacies and mail-order pharmacies. Ensure they conduct rigorous checks on their suppliers and that their procurement practices are fully compliant with federal and state regulations, including the Drug Supply Chain Security Act (DSCSA).
Medspas and Wellness Clinics: For aesthetic injectables, IV therapies, and other pharmaceutical products, demand verifiable proof of origin and compliance from your distributors. Understand the distinction between legitimate U.S.-sourced products and potentially unapproved or counterfeit alternatives.
Dental and Chiropractic Practices: For any medications dispensed or administered on-site, including controlled substances, ensure your suppliers are licensed and reputable. Regularly audit your procurement records and supplier agreements.

Proactive measures such as vendor credentialing, contractual safeguards, and periodic compliance audits are no longer optional—they are foundational to risk management. Ignorance of a supplier's debarred status or engagement in illicit drug importation offers no defense and can trigger severe penalties for healthcare providers.

The Shifting Landscape of Over-the-Counter Medications: Expanded Access and Provider Responsibilities

The FDA has continued its strategic efforts to enhance public health by expanding access to critical medications through over-the-counter (OTC) pathways, while simultaneously ensuring consumer safety through updated labeling requirements. These developments significantly impact the advice and education that healthcare providers must be prepared to offer patients.

FDA Mandates Labeling Updates for alli (Orlistat): The agency approved crucial updates to the 'Drugs Facts Label' for the OTC weight loss medication, alli (orlistat) 60 mg capsules, to include warnings about rare but serious risks of acute kidney injury, kidney stones, and other kidney-related issues. This update aligns the OTC product's warnings with those of its higher-strength prescription counterpart, Xenical.

FDA Approves Second Over-the-Counter Naloxone Nasal Spray, Rextovy: In a move to combat the opioid crisis, the FDA approved Rextovy, a 4 mg naloxone hydrochloride nasal spray, for OTC sale. This approval provides an additional, readily available option for individuals to reverse opioid overdose effects, empowering communities with a life-saving tool.

How These Changes Reshape Provider Engagement:

1. Comprehensive Patient Education for OTC Use: While OTC status means these medications don't require a prescription, patients frequently seek guidance from their healthcare providers. For alli (orlistat), providers across all specialties must be prepared to discuss potential renal risks when counseling patients on weight management strategies or reviewing medication lists. This is particularly relevant for practices engaging in preventive care, chronic disease management, or aesthetic services where weight loss discussions are common. * Telehealth: Implement standardized patient education modules and virtual intake forms that inquire about OTC medication use and relevant medical history (e.g., kidney disease). * Medspas/Wellness: Ensure that pre-treatment consultations include a thorough review of all medications, including OTCs, and provide clear guidance on weight loss interventions that align with patient safety. * Dental/Chiropractic: Be vigilant during patient intake. Unidentified kidney issues, potentially exacerbated by certain OTCs, could impact treatment plans or require referral.

2. Integrating Naloxone Awareness into Patient Care: The OTC availability of naloxone like Rextovy significantly broadens access, making it a vital public health tool. Healthcare providers are now tasked with a broader public health role in raising awareness. * Opioid Prescribing Practices: For dental practices prescribing opioids for post-procedural pain or chiropractic offices managing chronic pain where opioids may be part of a broader treatment plan, discussions about naloxone availability should be standard practice, especially for patients at higher risk of overdose or those with household members who are. * General Patient Education: All healthcare settings can play a role in educating patients and their families about the signs of opioid overdose and how to access and administer OTC naloxone. This is not just for patients receiving opioids; it's a community safety initiative. Empowering patients with this knowledge can reduce overdose fatalities.

These OTC developments underscore the need for healthcare providers to maintain up-to-date knowledge of the entire medication landscape, not just prescription drugs. It requires a shift towards a more holistic approach to patient counseling, emphasizing the provider's role in guiding informed self-care and public health initiatives.

PBM Transparency on the Horizon: CMS Seeks Input, Signaling Major Shifts in Drug Benefit Management

The Centers for Medicare & Medicaid Services (CMS) has initiated a critical Request for Information (RFI) to gather technical input on the services and business practices of Pharmacy Benefit Managers (PBMs) and their affiliates. This RFI is a direct precursor to implementing recent legislation aimed at restricting PBM remuneration and increasing data reporting, with changes slated for Calendar Year 2028.

Why This Matters to Your Practice: While PBMs are often seen as separate entities, their practices profoundly impact patient access to medications, drug costs, and ultimately, the financial health of healthcare providers. The CMS RFI signals a sustained federal push for greater transparency and accountability within the PBM sector, and its long-term effects could ripple across the entire healthcare ecosystem.

Impact on Medication Costs and Formularies: Increased transparency could lead to changes in drug pricing structures and potentially influence which drugs are included in formularies. This directly affects patient adherence, out-of-pocket costs, and the administrative burden on practices needing to secure prior authorizations or find alternative therapies.
Reimbursement for Drug-Related Services: Practices involved in medication management, dispensing, or complex care coordination may see shifts in how these services are reimbursed as PBM remuneration models evolve. Understanding the true cost of drugs and the role of PBMs will be crucial for negotiating favorable contracts with payers.
Corporate Practice of Medicine (CPOM) and Dispensing: For practices operating in states with stringent CPOM regulations or those considering direct dispensing models, changes to PBM compensation and data reporting could create both challenges and opportunities. Greater transparency might expose previous opaque practices, potentially informing new state-level regulatory efforts or influencing the viability of certain dispensing models.
Medicare Part D Implications: Practices serving Medicare Part D beneficiaries will be directly impacted. Changes in PBM practices could alter patient choice, access to specific pharmacies, and the overall benefit design, requiring practices to adapt their patient counseling and referral strategies.

Actionable Insight: Healthcare executives should actively monitor the outcomes of this CMS RFI and subsequent regulatory actions. Engage with industry associations and compliance experts to understand the potential financial and operational impacts. Proactively assess your current prescribing patterns, patient demographics, and financial models to prepare for a potentially more transparent, and potentially more volatile, drug benefit landscape. Preparing for 2028 now means you can adapt strategically rather than reactively.

Looking Ahead: A Call for Proactive and Integrated Compliance

The collective force of these regulatory developments — intensified FDA enforcement on supply chains, evolving OTC medication guidelines, and an accelerating push for PBM transparency — paints a clear picture: compliance can no longer be a siloed function. It must be an integrated, proactive, and strategic imperative woven into the very fabric of your operations.

The common threads binding these updates are patient safety, transparency, and accountability. Practices that prioritize these principles through robust internal controls, continuous staff education, and diligent monitoring will be best positioned to navigate the complexities ahead. The stakes are too high to operate without a comprehensive understanding of the regulatory environment.

What This Means For Your Practice

To thrive in this dynamic landscape, healthcare leaders must:

Strengthen Supply Chain Due Diligence: Implement and regularly audit vendor credentialing programs for all pharmaceutical and medical product suppliers. Verify licenses, debarment status, and adherence to federal and state drug integrity laws.
Enhance Patient Education and Medication Review Protocols: Update training for all clinical staff on the latest OTC medication warnings and expanded access initiatives. Ensure comprehensive medication reconciliation includes OTC products and proactive discussions about overdose reversal tools.
Strategically Monitor PBM Reforms: Engage with industry intelligence to understand how CMS's RFI will shape future PBM regulations. Assess potential impacts on your practice's economics, patient access to prescribed drugs, and internal dispensing capabilities. Prepare to adapt contracting and formulary guidance.
Invest in Integrated Compliance Solutions: Leverage technology and expert guidance to ensure your compliance framework is agile, adaptable, and covers the full spectrum of operational risks, from prescribing to procurement to patient interactions.

TrueEval remains your definitive partner in this journey, providing the insights and infrastructure necessary to transform complex regulatory challenges into clear, actionable compliance strategies. The future of healthcare demands not just adherence, but foresight.